|
AACTG 5024
TRIAL: Compares STI w/ IL-2, w/ ALVAC vaccine or with both vs. w/o
CRITERIA: On stable antiretroviral therapy for six months; CD4s > 350; viral load < 50
STATUS: 64-week study; currently enrolled 41 out of 100
CONTACT: Multiple sites, 800.TRIALS.A
AACTG 5068
TRIAL: Compares STI w/ vs. w/o use of ALVAC vaccine
CRITERIA: On first combination regimen; CD4s > 500 for at least 6 months;
viral load < 50
STATUS: 24-month study; currently
enrolled 7 out of 100
CONTACT: Multiple sites, 800.TRIALS.A
AACTG 5086
TRIAL: Compares immediate vs. deferred (four-month STI) treatment
in salvage situation
CRITERIA: Drug-resistant HIV;
CD4s > 150; "high" viral load
STATUS: 64-week study; currently
enrolled 3 out of 220
CONTACT: Multiple sites, 800.TRIALS.A
AACTG 5102
TRIAL: Compares STI w/ vs. w/o use of IL-2
CRITERIA: No history of drug failure; no steroids; CD4s > 500; viral load < 200
STATUS: Still in development; 80 slots
CONTACT: Multiple sites, 800.TRIALS.A
Cornell/New York Hospital
TRIAL: Compares STI w/ vs. w/o use
of IL-2, ALVAC or the two together
CRITERIA: On stable antiretroviral therapy for six months; no hepatitis B or C;
CD4s > 400; viral load < 50
STATUS: 25-week study; currently
enrolled none out of 92
CONTACT: 212.241.6886
|
CPCRA 064
TRIAL: Compares immediate vs. deferred
(4-month STI) treatment in salvage situation
CRITERIA: Drug-resistant HIV; viral load > 10,000; also enrolls
adolescents (> 13 yrs)
STATUS: 24-month study; currently
enrolled 150 out of 480
CONTACT: Multiple sites, 800.TRIALS.A
CPCRA "SMART"
TRIAL: Compares continuous
vs. on/off treatment strategies
CRITERIA: CD4s >350; also enrolls
adolescents (> 13 yrs)
STATUS: Still in development;
enrollment set for October 2001
CONTACT: Multiple sites, check www.smart-trial.org
Gladstone/UCSF
TRIAL: Compares continuous vs. intermittent treatment (six months on, two months off)
CRITERIA: On stable antiretroviral therapy; pre-treatment CD4 low > 100;
viral load < 50 for at least 3 months
STATUS: 24-month study; currently
enrolled 10 out of 20
CONTACT: 415.695.3820
NIH I-0020
TRIAL: Compares continuous vs. intermittent treatment (two months on, one month off)
CRITERIA: CD4s > 300; viral load < 50
STATUS: 22-month study; currently
enrolled none out of 70
CONTACT: 800.411.1222
Wistar/U Penn
TRIAL: Compares continuous vs. intermittent treatment, followed by unlimited STI
CRITERIA: CD4s > 400; viral load < 100
for 3 years
STATUS: 56-week study; currently
enrolled 20 out of 52
CONTACT: 215.985.4448, ext. 226
| 
